Your Article Summary
See Latest ArticlesErectile dysfunction, cardiovascular diseases and depression: interaction of therapy
Expert Opinion in Pharmacotherapy, 07/02/09
El-Sakka AI et al. - The potential effect of medications of each condition on the other conditions had gained a lot of interest. The aim of the current review is to discuss the integrative view of association between cardiovascular diseases, erectile dysfunction and depression, and to address the two direction impact of pharmacotherapy for IHD and depression on erectile function.
Related Articles
Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis
Arthritis Care and Research, 11/03/09
Relevance Score: 95%
Survival after myocardial infarction worse with first episode major depression than recurrent major depression
Evidence-Based Mental Health, 11/02/09
Relevance Score: 95%
Quality of life and depression among metastatic breast cancer patients
Medical Oncology, 10/05/09
Relevance Score: 95%
Serious diabetes-specific emotional problems in patients with type 2 diabetes who have different levels of comorbid depression: A Polish study from the European Depression in Diabetes (EDID) Research Consortium
European Psychiatry, 11/06/09
Relevance Score: 94%
A systematic review of longitudinal studies on the association between depression and smoking in adolescents
BMC Public Health, 10/01/09
Relevance Score: 94%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Non-adherence to statin therapy: a major challenge for preventive cardiology
Expert Opinion in Pharmacotherapy, 12/08/09
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09
A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management
Pharmacoepidemiology and Drug Safety, 12/08/09
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Subcutaneous Sumatriptan Pharmacokinetics: Delimiting the Monoamine Oxidase Inhibitor Effect
Headache: The Journal of Head and Face Pain, 12/08/09
Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin
American Journal of Health-System Pharmacy, 12/08/09
Potential interactions between cilostazol and probucol: A two-part, single-dose, open-label study in healthy Korean male volunteers
Clinical Therapeutics, 12/07/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Central Levodopa Influx and the Clinical Motor Response to Levodopa in Patients With Parkinson Disease Complicated With Motor Fluctuations and Dyskinesias
Clinical Neuropharmacology, 12/08/09
Levodopa-Induced Dyskinesias in Parkinson Disease Are Independent of the Extent of Striatal Dopaminergic Denervation: A Pharmacological and SPECT Study
Clinical Neuropharmacology, 12/08/09
Rapid Enhancement of Glutamatergic Neurotransmission in Bipolar Depression Following Treatment with Riluzole
Neuropsychopharmacology, 12/08/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09
Inflammatory breast cancer: what are the treatment options
Expert Opinion in Pharmacotherapy, 12/08/09
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Expert Opinion on Investigational Drugs, 12/08/09